ClinicalTrials.gg
Active, not recruitingNCT04188418Updated Aug 11, 2026

Fentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients

A Phase 3 interventional study of Fentanyl Citrate Buccal Tablet and Morphine in Hematopoietic and Lymphoid Cell Neoplasm and Malignant Solid Neoplasm, sponsored by M.D. Anderson Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by M.D. Anderson Cancer Center · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 99 studies in Hematologic Neoplasms by M.D. Anderson Cancer Center — 21 open to participants now, 42 under way, 1 of them phase 3. Hematologic Neoplasms · M.D. Anderson Cancer Center.

Planned enrollment
10th of 69
150 · median 40
Started
2020
with 23 others
Phase 3
4 of 99
none open now
Primary completion
2027-08
later than 22 of 41 live
Registered
49th of 99
by date

Among the 99 studies in Hematologic Neoplasms by M.D. Anderson Cancer Center, this one is the 10th largest by planned enrollment of the 69 interventional ones that give a count, is one of 24 that started in 2020, is one of 4 in phase 3, reaches primary completion later than 22 of the 41 other live ones, and was the 49th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

21 of the 99 studies in Hematologic Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

Where they have run

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Hematologic Neoplasms by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

This phase II trial studies fentanyl buccal tablet or morphine to see how well it works compared to a placebo in controlling shortness of breath during or after physical activity in cancer patients. Fentanyl sublingual tablet and morphine are opioids normally used to control pain that may also help to prevent or control shortness of breath during or after physical activity in cancer patients.

Read the detailed description

PRIMARY OBJECTIVE:

I. To compare the effect of prophylactic fentanyl buccal tablet (FBT), morphine sulfate, and placebo on the increase in the intensity of exertional dyspnea (0-10 point modified Borg scale) measured before versus at the end of a shuttle walk test (SWT).

SECONDARY OBJECTIVES:

I. To compare the effects of prophylactic FBT, morphine sulfate, and placebo on SWT distance and dyspnea unpleasantness, average daily dyspnea (intensity and unpleasantness, oxygen cost diagram), personalized daily activity (ability to complete activity), personalized dyspnea response, symptom burden (Edmonton Symptom Assessment System [ESAS]), quality of life (EuroQol-5 Dimension-5 Level [EQ-5D-5L]), and dyspnea severity and functional impairment based on the Patient Reported Outcomes Measurement Information System (PROMIS) dyspnea instruments.

II. To explore the effects of prophylactic FBT, morphine sulfate, and placebo on neurocognitive function, addictive potential (Drug Effects Questionnaire), adverse effects (Common Terminology Criteria for Adverse Events [CTCAE], Patient-Reported Outcomes version of CTCAE [PRO-CTCAE]), and pattern of opioid use.

OUTLINE: Patients are randomized to 1 of 3 groups.

GROUP I: Patients complete shuttle walk test on days 1, 5, 8, 12, 15, and 19. Patients also receive FBT sublingually daily on days 6-19.

GROUP II: Patients complete shuttle walk test on days 1, 5, 8, 12, 15, and 19. Patients also receive morphine orally (PO) daily on days 6-19.

GROUP III: Patients complete shuttle walk test on days 1, 5, 8, 12, 15, and 19. Patients also receive placebo (sublingually or PO) daily on days 6-19.

03

Conditions studied

  • Hematopoietic and Lymphoid Cell Neoplasm
  • Malignant Solid Neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of cancer with evidence of active disease
  2. Dyspnea on exertion with an average intensity level ≥4/10 on a modified Borg scale
  3. Outpatient at participating centers
  4. Ambulatory and able to walk, with or without walking aid
  5. On strong opioids with morphine equivalent daily dose (MEDD) of 60-400 mg for ≥1 wk (i.e. at least 4 out of 7 days), with stable (i.e. ±30%) regular dose over the last 3 d
  6. performance status ≥40%
  7. Age ≥18 yrs
  8. Able to complete study assessments
  9. Able to speak English or Spanish
  10. Reside within 65 miles of participating centers or expected to visit MD Anderson in person at least once a month

Exclusion criteria

Exclusion Criteria:

  1. Dyspnea at rest ≥7/10 on modified Borg scale at enrollment
  2. Supplemental oxygen requirement >6 L/min
  3. Delirium (i.e. Memorial Delirium Assessment Scale ≥13)
  4. History of unstable angina or myocardial infarction 1 mo prior to enrollment
  5. Hemodynamic instability requiring hospitalization
  6. History of substance use disorder or abnormal urinary drug screen within the past year, or at risk of opioid abuse as determined by Screener and Opioid Assessment for Patients with Pain (SOAPP14) ≥7
  7. History of or known allergy to fentanyl or morphine sulfate
  8. Using scheduled benzodiazepines at the time of enrollment and cannot stop during the study
  9. Severe anemia ( \<7 g/L) if documented in the last month and not corrected prior to study enrollment*
  10. ≥5x if documented in the last month and not lowered to \<5x normal prior to enrollment*
  11. Diagnosis of acute pulmonary embolism within past 2 wks
  12. Diagnosis of pulmonary hypertension
  13. Diagnosis of malignant pleural effusion with therapeutic thoracentesis expected in the next 2 wks
  14. Currently pregnant or breastfeeding
  15. Unwilling to provide
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Group I (shuttle walk test, FBT)

    Patients complete shuttle walk test on days 1, 5, 8, 12, 15, and 19. Patients also receive FBT sublingually daily on days 6-19.

    Drug: Fentanyl Citrate Buccal Tablet · Other: Physical Performance Testing · Other: Quality-of-Life Assessment · Other: Questionnaire Administration

  • Experimental
    Group II (shuttle walk test, morphine)

    Patients complete shuttle walk test on days 1, 5, 8, 12, 15, and 19. Patients also receive morphine PO daily on days 6-19.

    Drug: Morphine · Other: Physical Performance Testing · Other: Quality-of-Life Assessment · Other: Questionnaire Administration

  • Active comparator
    Group III (shuttle walk test, placebo)

    Patients complete shuttle walk test on days 1, 5, 8, 12, 15, and 19. Patients also receive placebo (sublingually or PO) daily on days 6-19.

    Other: Physical Performance Testing · Other: Placebo Administration · Other: Quality-of-Life Assessment · Other: Questionnaire Administration

Interventions

  • DrugFentanylStudies of FentanylFentanyl pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given transmucosally

    Also known as: Fentora

  • Given PO

  • OtherPhysical Performance Testing

    Complete shuttle walk test

    Also known as: Physical Fitness Testing, Physical Function Testing

  • OtherPlacebo Administration

    Given PO

  • OtherQuality-of-Life Assessment

    Ancillary studies

    Also known as: Quality of Life Assessment

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Change in modified Borg scale dyspnea intensity before and after the Shuttle Walk Test (SWT)

    Will first determine whether the three treatment groups are different; if so, will test the three pairwise comparisons with intention-to-treat analyses. Repeated-measures analysis of variance (ANOVA) will be implemented using linear mixed effects models with the difference in intervention period SWT modified Borg scale dyspnea intensity before and after SWT as the response variable and the treatment group and observation period SWT measures as predictor variables.

    Time frame: Days 5, 8, 12, 15, and 19

Secondary outcomes

  1. SWT distance

    Will be analyzed using linear mixed effects models similar to the primary analysis.

    Time frame: Days 5, 8, 12, 15, and 19

  2. Dyspnea unpleasantness

    Will be analyzed using linear mixed effects models similar to the primary analysis.

    Time frame: Days 5, 8, 12, 15, and 19

  3. Daily dyspnea intensity and unpleasantness

    Will be analyzed using linear mixed effects models similar to the primary analysis.

    Time frame: Days 1-19

  4. Personalized daily activity

    Will be analyzed using linear mixed effects models similar to the primary analysis.

    Time frame: Days 1-4, 6-7, 9-11, 13-14, and 16-18

  5. Oxygen cost diagram

    Will be analyzed using linear mixed effects models similar to the primary analysis.

    Time frame: Days 1-19

  6. Symptom burden Questionnaires

    Will be measured by the Edmonton Symptom Assessment System and analyzed using linear mixed effects models similar to the primary analysis.

    Time frame: Days 1-19

  7. Quality of life Questionnaires

    Will be measured by the EuroQol-5 Dimension-5 Level Questionnaire and analyzed using linear mixed effects models similar to the primary analysis.

    Time frame: Days 1-19

  8. Neurocognitive function

    Will perform paired t-test or ANOVA if the data are normally distributed and the Wilcoxon rank-sum test or Kruskal-Wallis if the data are non-normal.

    Time frame: Up to day 19

  9. Addictive potential

    Will be measured by the Drug Effects Questionnaire. Will perform paired t-test or ANOVA if the data are normally distributed and the Wilcoxon rank-sum test or Kruskal-Wallis if the data are non-normal.

    Time frame: Up to day 19

  10. Frequency, severity, and interference of adverse effects

    Will be measured by the Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE). Will perform paired t-test or ANOVA if the data are normally distributed and the Wilcoxon rank-sum test or Kruskal-Wallis if the data are non-normal.

    Time frame: Up to day 19

  11. Total opioid dose

    Will perform paired t-test or ANOVA if the data are normally distributed and the Wilcoxon rank-sum test or Kruskal-Wallis if the data are non-normal.

    Time frame: Up to day 19

  12. Number of rescue doses per day

    Will perform paired t-test or ANOVA if the data are normally distributed and the Wilcoxon rank-sum test or Kruskal-Wallis if the data are non-normal.

    Time frame: Up to day 19

  13. Dyspnea severity and functional impairment

    Will be measured using the Patient Reported Outcomes Measurement Information System (PROMIS) dyspnea instruments.

    Time frame: Day 1, 5, 12, 19

07

Study locations

1 site
08

References and documents

Publications

  • Hui D, Pacheco S, Nguyen L, Jennings K, de la Cruz V, Stanton P, Laureano R, Ontai A, Mahler D, Bruera E. Efficacy of fentanyl buccal tablet and morphine for exertional dyspnoea in patients with cancer: a double-blind, placebo-controlled, randomised clinical trial. Thorax. 2026 Mar 13;81(4):344-356. doi: 10.1136/thorax-2025-222970. PubMed 41115797 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2020 (actual). Primary completion is estimated for Aug 2027, 82 months after the start.

Of 41 phase 3 interventional studies under Hematologic Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 81. This study's planned 82 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2019
First posted
Dec 5, 2019
StartActual
Oct 23, 2020
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04188418
Responsible party
Sponsor
First posted
Dec 5, 2019
Start date
Oct 23, 2020
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Aug 11, 2026

Study contacts

David Hui
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fentanyl · Morphine

Start the discussion